Urolog. pro Praxi, 2004; 6: 246-248

Současné trendy v léčbě benigní hyperplazie prostaty

MUDr. Libor Zámečník, MUDr. Květoslav Novák, prof. MUDr. Jan Dvořáček DrSc
Urologická klinika 1. LF UK a VFN Praha

Keywords: benign prostatic hyperplasia, pharmacological therapy, minimally invasive therapy.

Published: December 31, 2004  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zámečník L, Novák K, Dvořáček J. Současné trendy v léčbě benigní hyperplazie prostaty. Urol. praxi. 2004;5(6):246-248.

Benigní hyperplazie prostaty (BHP) je nejčastějším benigním nádorem u mužů ve vyšším věku. Je charakterizována zvětšením prostaty, které má svými důsledky mnohdy výrazný vliv na kvalitu pacientova života. V posledních patnácti letech zaznamenala léčba tohoto onemocnění prudký rozvoj, a to v celém spektru léčebných modalit - od pouhého sledování až po otevřenou prostatektomii. Autoři shrnují současné možnosti moderní léčby benigní hyperplazie prostaty, jak medikamentózní, tak minimálně invazivní a zaměřují se také na hodnocení těchto metod v rámci přijatých doporučených postupů.

CURRENT TRENDS IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA.

Benign prostatic hyperplasia (BPH) is the most common benign tumour in older men. It is characterised with an enlargement of prostate, which consequences frequently have significant impact on patient-s life quality. Therapy of this disease has recognised a tremendous progress during the last fifteen years moreover within the whole spectrum of treatment modalities - beginning from a watchful waiting and ending with an open prostatectomy. Authors summarise current possibilities of modern therapy of benign prostatic hyperplasia either a pharmacological or a minimally invasive and focus on the evaluation of these methods within accepted guidelines.

Download citation




Urology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.